The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer.
Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Neoplasia (New York, N.Y.) 2008;10(8):897-907.
Prostate cancer cell lines provide ideal in vitro systems for the identification and analysis of prostate tumor suppressors and oncogenes. A detailed characterization of the architecture of prostate cancer cell line genomes would facilitate the study of precise roles of various genes in prostate tumorigenesis in general. To contribute to such a characterization, we used the GeneChip 500K single nucleotide polymorphic (SNP) array for analysis of genotypes and relative DNA copy number changes across the genome of 11 cell lines derived from both normal and cancerous prostate tissues. For comparison purposes, we also examined the alterations observed in the cell lines in tumor/normal pairs of clinical samples from 72 patients. Along with genome-wide maps of DNA copy number changes and loss of heterozygosity for these cell lines, we report previously unreported homozygous deletions and recurrent amplifications in prostate cancers in this study. The homozygous deletions affected a number of biologically important genes, including PPP2R2A and BNIP3L identified in this study and CDKN2A/CDKN2B reported previously. Although most amplified genomic regions tended to be large, amplifications at 8q24.21 were of particular interest because the affected regions are relatively small, are found in multiple cell lines, are located near MYC, an oncogene strongly implicated in prostate tumorigenesis, and are known to harbor SNPs that are associated with inherited susceptibility for prostate cancer. The genomic alterations revealed in this study provide an important catalog of positional information relevant to efforts aimed at deciphering the molecular genetic basis of prostate cancer.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
H Suzuki; D Freije; D R Nusskern; K Okami; P Cairns; D Sidransky; W B Isaacs; G S BovaCancer research 1998;58(2):204-9.
Yu Cheng; Wennuan Liu; Seong-Tae Kim; Jishan Sun; Lingyi Lu; Jielin Sun; Siqun Lilly Zheng; William B Isaacs; Jianfeng XuCancer genetics 2011;204(7):375-81.
C Van Den Berg; X Y Guan; D Von Hoff; R Jenkins; Bittner; C Griffin; O Kallioniemi; Visakorpi; McGill; J HerathClinical cancer research : an official journal of the American Association for Cancer Research 1995;1(1):11-8.
Appears in this Publication
Author of this Publication